SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma surges on reporting 24% jump in Q1 consolidated net profit

24 Aug 2016 Evaluate

Aurobindo Pharma is currently trading at Rs. 769.45, up by 33.15 points or 4.50% from its previous closing of Rs. 736.30 on the BSE.

The scrip opened at Rs. 765.00 and has touched a high and low of Rs. 777.50 and Rs. 751.30 respectively. So far 311493 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 891.50 on 30-Dec-2015 and a 52 week low of Rs. 582.00 on 25-Feb-2016.

Last one week high and low of the scrip stood at Rs. 777.50 and Rs. 730.10 respectively. The current market cap of the company is Rs. 45151.69 crore.

The promoters holding in the company stood at 53.79%, while institutions and non-institutions held 34.08% and 12.13% respectively.

Aurobindo Pharma has reported 4.15% fall in its net profit at Rs 391.03 crore for the quarter as compared to Rs 407.95 crore for the same quarter in the previous year. However, total income of the company increased by 6.91% at Rs 2399.54 crore for quarter under review as compared to Rs 2244.37 crore for the quarter ended June 30, 2015.

On the consolidated basis, the company has reported 23.81% jump in its net profit after taxes, minority interest and share of profit of joint ventures at Rs 584.96 crore for the quarter ended June 30, 2016 as compared to Rs 472.45 crore for the same quarter in the previous year. Total Income of the company increased by 12.42% to Rs 3741.79 crore for quarter under review from Rs 3328.30 crore for the quarter ended June 30, 2015.

 

Aurobindo Pharma Share Price

1620.10 60.05 (3.85%)
03-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1904.65
Dr. Reddys Labs. 1374.55
Cipla 1458.45
Zydus Lifesciences 1141.00
Lupin 2476.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: